Gianluca Masi


Ontology type: schema:Person     


Person Info

NAME

Gianluca

SURNAME

Masi

Publications in SciGraph latest 50 shown

  • 2019-01 Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma in BRITISH JOURNAL OF CANCER
  • 2018-08 Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients in INVESTIGATIONAL NEW DRUGS
  • 2017-12 TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group in BMC CANCER
  • 2017-09 The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres in ANNALS OF SURGICAL ONCOLOGY
  • 2017-07-25 The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab in BRITISH JOURNAL OF CANCER
  • 2017-02 First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2017-01 Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2015-12 Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer in BMC CANCER
  • 2015-10 First-line chemotherapy for mCRC—a review and evidence-based algorithm in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2014-09 EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan in TARGETED ONCOLOGY
  • 2014-08 Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients in THE PHARMACOGENOMICS JOURNAL
  • 2013-06 Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab in BRITISH JOURNAL OF CANCER
  • 2012-09 Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics? in CURRENT COLORECTAL CANCER REPORTS
  • 2012-06 Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers in ANGIOGENESIS
  • 2011-12 Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer in BMC CANCER
  • 2011-07 Anti-HER agents in gastric cancer: from bench to bedside in NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
  • 2011-04 Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2010-08 Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2009-12 Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis in BMC CANCER
  • 2009-11 Refractory neuroendocrine tumor—response to liposomal doxorubicin and capecitabine in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2009-08 KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2009-06 A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2009-04 A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2009-02 Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer in THE PHARMACOGENOMICS JOURNAL
  • 2009 First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients in PLATINUM AND OTHER HEAVY METAL COMPOUNDS IN CANCER CHEMOTHERAPY
  • 2008-09 Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy in BRITISH JOURNAL OF CANCER
  • 2008-04 A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients in BRITISH JOURNAL OF CANCER
  • 2007-07 Chemotherapy intensification in CURRENT COLORECTAL CANCER REPORTS
  • 2006-11 Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2006-01 Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer in ANNALS OF SURGICAL ONCOLOGY
  • 1999-06 Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.488566.1", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.24704.35", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417287.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7841.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415103.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410345.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7010.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.12711.34", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5395.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.440387.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414498.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.29980.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.9657.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4527.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.144189.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413179.9", 
            "type": "Organization"
          }
        ], 
        "familyName": "Masi", 
        "givenName": "Gianluca", 
        "id": "sg:person.01062670207.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062670207.83"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:50", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_560.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01062670207.83'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01062670207.83'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01062670207.83'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01062670207.83'


     

    This table displays all metadata directly associated to this object as RDF triples.

    46 TRIPLES      10 PREDICATES      26 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01062670207.83 schema:affiliation Nc4a672900c0341988ae34126a42f5c57
    2 https://www.grid.ac/institutes/grid.12711.34
    3 https://www.grid.ac/institutes/grid.144189.1
    4 https://www.grid.ac/institutes/grid.24704.35
    5 https://www.grid.ac/institutes/grid.29980.3a
    6 https://www.grid.ac/institutes/grid.410345.7
    7 https://www.grid.ac/institutes/grid.413179.9
    8 https://www.grid.ac/institutes/grid.414498.4
    9 https://www.grid.ac/institutes/grid.415103.2
    10 https://www.grid.ac/institutes/grid.417287.f
    11 https://www.grid.ac/institutes/grid.440387.c
    12 https://www.grid.ac/institutes/grid.4527.4
    13 https://www.grid.ac/institutes/grid.5395.a
    14 https://www.grid.ac/institutes/grid.7010.6
    15 https://www.grid.ac/institutes/grid.7841.a
    16 https://www.grid.ac/institutes/grid.9657.d
    17 schema:familyName Masi
    18 schema:givenName Gianluca
    19 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062670207.83
    20 schema:sdDatePublished 2019-03-07T14:50
    21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    22 schema:sdPublisher Nd0e5cc9cbf764947a8e6d5ae178f9426
    23 sgo:license sg:explorer/license/
    24 sgo:sdDataset persons
    25 rdf:type schema:Person
    26 Nc4a672900c0341988ae34126a42f5c57 schema:affiliation https://www.grid.ac/institutes/grid.488566.1
    27 sgo:isCurrent true
    28 rdf:type schema:OrganizationRole
    29 Nd0e5cc9cbf764947a8e6d5ae178f9426 schema:name Springer Nature - SN SciGraph project
    30 rdf:type schema:Organization
    31 https://www.grid.ac/institutes/grid.12711.34 schema:Organization
    32 https://www.grid.ac/institutes/grid.144189.1 schema:Organization
    33 https://www.grid.ac/institutes/grid.24704.35 schema:Organization
    34 https://www.grid.ac/institutes/grid.29980.3a schema:Organization
    35 https://www.grid.ac/institutes/grid.410345.7 schema:Organization
    36 https://www.grid.ac/institutes/grid.413179.9 schema:Organization
    37 https://www.grid.ac/institutes/grid.414498.4 schema:Organization
    38 https://www.grid.ac/institutes/grid.415103.2 schema:Organization
    39 https://www.grid.ac/institutes/grid.417287.f schema:Organization
    40 https://www.grid.ac/institutes/grid.440387.c schema:Organization
    41 https://www.grid.ac/institutes/grid.4527.4 schema:Organization
    42 https://www.grid.ac/institutes/grid.488566.1 schema:Organization
    43 https://www.grid.ac/institutes/grid.5395.a schema:Organization
    44 https://www.grid.ac/institutes/grid.7010.6 schema:Organization
    45 https://www.grid.ac/institutes/grid.7841.a schema:Organization
    46 https://www.grid.ac/institutes/grid.9657.d schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...